Literature DB >> 12625489

Hyperlipidaemias and serum cytokines in patients with coronary artery disease.

Katarzyna Mizia-Stec1, Barbara Zahorska-Markiewicz, Tadeusz Mandecki, Joanna Janowska, Andrzej Szulc, Ewa Jastrzekbska-Maj, Zbigniew Gasior.   

Abstract

OBJECTIVE: The inflammatory processes as well as the lipid disturbances play an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the influence of the hyperlipidaemias on serum levels of tumour necrosis factor (TNF) alpha, the soluble form of TNF receptor (sTNFR) 1 and 2, Interleukin (IL)-10 in patients with stable coronary artery disease (CAD). METHODS AND
RESULTS: The study group comprised 94 consecutive admissions with stable CAD: 39 patients with hypercholesterolaemia (group HC), 22 patients with mixed hyperlipidaemia (group HL) and 33 patients with normal lipids (group NL). Twenty healthy volunteers were the controls (group C). Serum TNFalpha levels were higher in all CAD groups (p < 0.001) than in healthy subjects. Mean serum concentrations of sTNFR 1 were significantly higher in group NL (p < 0.05) in comparison both to group HC and controls. IL-10 levels were higher in group HC than in controls (p < 0.5). In all CAD patients TNFalpha showed a negative correlation with HDL-cholesterol (p < 0.001) and a positive correlation with triglycerides (p < 0.00 1). Moreover, sTNFR 1 and IL-10 showed a negative (p < 0.05) and sTNFR 2 a positive correlation with LDL-cholesterol (p < 0.001).
CONCLUSIONS: CAD patients are characterized by increased serum concentrations of TNFalpha. It seems likely that immune activation (TNFalpha, sTNFR 1, sTNFR 2, and IL- 10) in CAD patients is related to serum lipids levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12625489     DOI: 10.2143/AC.58.1.2005253

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  6 in total

1.  Decreased serum adiponectin in adolescents and young adults with familial primary hypercholesterolemia.

Authors:  Lian-Yu Lin; Chiau-Suong Liau; Wei-Shiung Yang; Ta-Chen Su
Journal:  Lipids       Date:  2005-02       Impact factor: 1.880

2.  Establishment of a cut-point value of serum TNF-alpha levels in the metabolic syndrome.

Authors:  Carmen M Gurrola-Díaz; Sergio Sánchez-Enriquez; Edith Oregon-Romero; Pedro M García-López; Pedro Garzón de la Mora; Blanca E Bastidas-Ramírez; Mercedes González-Hita; José F Muñoz-Valle
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  Adiponectin in relation to exercise and physical performance in patients with type 2 diabetes and coronary artery disease.

Authors:  Hani Zaidi; Rune Byrkjeland; Ida U Njerve; Sissel Åkra; Svein Solheim; Harald Arnesen; Ingebjørg Seljeflot; Trine B Opstad
Journal:  Adipocyte       Date:  2021-12       Impact factor: 4.534

4.  Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study.

Authors:  Wahyu Wulaningsih; Hans Garmo; Lars Holmberg; Niklas Hammar; Ingmar Jungner; Göran Walldius; Mieke Van Hemelrijck
Journal:  J Cancer Epidemiol       Date:  2012-08-30

5.  High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma.

Authors:  Pei-Dong Chi; Wen Liu; Hao Chen; Jing-Ping Zhang; Yuehao Lin; Xin Zheng; Wanli Liu; Shuqin Dai
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

Review 6.  Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.

Authors:  Un Ju Jung; Myung-Sook Choi
Journal:  Int J Mol Sci       Date:  2014-04-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.